Lead Product(s): HTL0022562
Therapeutic Area: Neurology Product Name: HTL0022562
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals
Deal Size: $380.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration December 01, 2020
Biohaven will get exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. The portfolio includes the lead candidate HTL0022562.